NEW YORK and CAESAREA, Israel, July
30, 2019 /PRNewswire/ -- DarioHealth Corp. (Nasdaq:
DRIO), ("DarioHealth" or "Dario"), a leading global, digital
therapeutics company, announced today the addition of a new digital
monitoring solution on its Dario app platform that will allow
patients to monitor their blood pressure throughout the day, in
addition to their blood glucose levels. The Dario Blood Pressure
Monitoring System assists patients with hypertension and is a
critical part of DarioHealth's strategy to go beyond diabetes to
reach patients with a variety of chronic conditions.
The Dario Blood Pressure Monitoring System is a medical device
composed of a digital monitor and a blood pressure cuff, that
synchronizes with the Dario mobile app which allows users to track
their blood pressure and a variety of health markers, along with
the daily actions that influence them. Combining the Dario Blood
Pressure Monitoring System, with the Dario Blood Glucose Monitoring
System, creates a harmonized digital health solution, enabling
users to better monitor their health and make data driven choices.
Together with Dario's software and professional coaching, we
believe that users with hypertension and diabetes will benefit from
a clear broad picture of their condition in a user-friendly format
on their iPhone or Android mobile device.
"Our digital diabetes management solution has proven to be a
valuable daily companion to those suffering from this chronic
condition and is able to meet their needs and expectations. We have
further expanded our offering to address the needs of those with
hypertension, providing a sophisticated solution to millions
affected by this condition" commented Erez
Raphael, Chief Executive Officer of DarioHealth.
Today, 75 million American have High blood pressure[1] including
73.6% of adults with diabetes2. By offering a fast, easy
way to monitor these two strongly correlated chronic conditions,
Dario aims to help more people live healthier lives. Dario also
provides healthcare professionals with access to the accumulated
information and enables them to adjust their interventions and
evaluate their clinical effectiveness based on hard data.
Like the Dario Blood Glucose Monitoring System, the Dario Blood
Pressure Monitoring System is FDA-cleared.
The Dario Blood Pressure Monitoring System will be offered as a
companion system where the Dario Blood Glucose Monitoring System is
available, online and via Dario distributors.
About DarioHealth Corp.
DarioHealth Corp. (NASDAQ: DRIO) is a leading Global Digital
Therapeutics (DTx) company revolutionizing the way people manage
their health across the chronic condition spectrum. By delivering
evidence-based interventions that are driven by precision data
analytics, high quality software, and personalized coaching,
DarioHealth have developed a novel approach that empowers
individuals to adjust their lifestyle in a unique and holistic way.
DarioHealth's cross functional team operates at the intersection of
life science, behavioral science, and software technology to
deliver seamlessly integrated and highly engaging therapeutic
interventions. Already one of the highest rated diabetes solutions,
its user-centric approach is loved by tens of thousands of
customers around the globe. DarioHealth is rapidly expanding
solutions for additional chronic conditions such as hypertension
and moving into new geographic markets, using a performance-based
approach to improve the health of users managing chronic disease.
To learn more about DarioHealth and its digital health solutions
via the Dario mobile app, please go to:
https://www.dariohealth.com/ .
Cautionary Note Regarding Forward-Looking Statements
This news release and the statements of representatives and
partners of DarioHealth Corp. (the "Company") related thereto
contain or may contain forward-looking statements within the
meaning of the Private Securities Litigation Reform Act of 1995.
Statements that are not statements of historical fact may be deemed
to be forward-looking statements. Without limiting the generality
of the foregoing, words such as "plan," "project," "potential,"
"seek," "may," "will," "expect," "believe," "anticipate," "intend,"
"could," "estimate," or "continue" are intended to identify
forward-looking statements. For example, when the Company states
that utilizing the Dario Blood Pressure Monitoring System, together
with the Dario Blood Glucose Monitoring System, creates a
harmonized digital health solution, enabling users to better
monitor their health and make data driven and its belief that
users with hypertension and diabetes that utilize Dario's software
and professional coaching will benefit from a clear, broad picture
of their condition in a user-friendly format on their iPhone or
Android mobile device, it is using forward-looking statements.
Readers are cautioned that certain important factors may affect the
Company's actual results and could cause such results to differ
materially from any forward-looking statements that may be made in
this news release. Factors that may affect the Company's results
include, but are not limited to, regulatory approvals, product
demand, market acceptance, impact of competitive products and
prices, product development, commercialization or technological
difficulties, the success or failure of negotiations and trade,
legal, social and economic risks, and the risks associated with the
adequacy of existing cash resources. Additional factors that could
cause or contribute to differences between the Company's actual
results and forward-looking statements include, but are not limited
to, those risks discussed in the Company's filings with the U.S.
Securities and Exchange Commission. Readers are cautioned that
actual results (including, without limitation, the timing for and
results of the Company's commercial and regulatory plans for Dario)
may differ significantly from those set forth in the
forward-looking statements. The Company undertakes no obligation to
publicly update any forward-looking statements, whether as a result
of new information, future events or otherwise, except as required
by applicable law.
https://www.cdc.gov/bloodpressure/faqs.htm
https://www.ncbi.nlm.nih.gov/books/NBK279027/
Contacts:
DarioHealth Corporate Contact: Claudia
Levi, Content & Communications Manager,
claudia@mydario.com, +1-347-767-4220
For Media Inquiries: Catherine Polisi Jones, Polisi Jones
Communications, cjones@polisijones.com, +1.917.330.8934
View original content to download
multimedia:http://www.prnewswire.com/news-releases/dariohealth-launches-new-blood-pressure-monitoring-system-300893041.html
SOURCE DarioHealth Corp.